IKAR

Pharmaceutical ManufacturingRussia51-200 Employees

IKAR is a Russia-based pharmaceutical manufacturer focused on developing and commercializing therapies for critically ill patients. Its lead product, INOMAX, is an inhaled nitric oxide therapy approved by the FDA for hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. The INOMAX therapy package combines the drug, a delivery system, on-site training, and round-the-clock technical support, and it is marketed in the United States, Puerto Rico, Canada, Australia, Mexico, and Japan.

Operating in the pharmaceutical manufacturing sector with a specialty in critical care, IKAR targets healthcare facilities that treat seriously ill neonates and other patients requiring respiratory support. By providing a regulated therapy alongside patient-care delivery infrastructure and ongoing service, the company aims to address significant clinical needs in neonatal respiratory management.

Sign up for free to view info

Email Format Employee directory